INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$109.35
+4.62 (+4.41%)
Open$106.45
Previous Close$104.73
Day High$110.41
Day Low$105.04
52W High$155.29
52W Low$26.19
Volume—
Avg Volume430.0K
Market Cap1.61B
P/E Ratio—
EPS$-8.88
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-83.4% upside
Current
$109.35
$109.35
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.26M | 1.50M | 384.43M |
| Net Income | -135,931,939 | -145,606,694 | -115,444,062 |
| Profit Margin | -10,773.5% | -10,234.8% | -30.0% |
| EBITDA | -128,640,369 | -145,451,500 | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -16.0% | -16.0% | -5.8% |
| Debt/Equity | 12.58 | 12.58 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |